Caxton Associates (UK)’s Novavax NVAX Stock Holding History

Caxton Associates (UK)’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,088	Closed	-$90.3K	–	907
2026 Q1	$90.3K	Buy	+11,088	New	+$101K	﹤0.01%	749
2025 Q2	–	Sell	-24,681	Closed	-$158K	–	838
2025 Q1	$158K	Buy	+24,681	New	+$204K	0.01%	722

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Caxton Associates (UK)'s NVAX Position: Q2 2026 in Review

Caxton Associates (UK) sold out of Novavax (NVAX) in Q2 2026, closing a stake of 11,088 shares — an estimated $90.3K sold.

Caxton Associates (UK) first reported a position in NVAX in Q1 2025 and held it in 2 quarters. The position peaked at $158K in Q1 2025. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Caxton Associates (UK) reported no remaining Novavax position as of Q2 2026 after selling out during the quarter.
Caxton Associates (UK) sold 11,088 Novavax shares in Q2 2026, an estimated $90.3K.
Caxton Associates (UK) first reported a position in Novavax in Q1 2025 and held it in 2 quarters.
Caxton Associates (UK)'s Novavax position peaked at $158K in Q1 2025.
266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.